Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font

Welcome to Robins Social Network

Be part of the community and join us today!

Active Pharmaceutical Ingredients Market - Emerging Industry Trends & Global Future Forecasts

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Report Objectives:

To define, describe, and forecast the global APIs market on the basis of type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region

To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To strategically analyze micromarkets with respect to the individual growth trends, future prospects, and contributions to the overall market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)

To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

To track and analyze competitive developments such as partnerships, agreements, collaborations, joint ventures, alliances, mergers & acquisitions, approvals, expansions, and R&D activities in the global APIs market.

Download PDF Brochure@

“The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.”

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. The demand for biotech-derived molecules is growing significantly owing to their specificity in action. The demand for biologics is also increasing because they are similar to natural biological compounds found in the human body as compared to synthetic APIs, making this the fastest-growing segment in the market.

“The captive API manufacturers segment estimated to account for the largest share in 2019.”

Based on type of manufacturer, the APIs market can be divided into captive API manufacturers and merchant API manufacturers. In 2019, the captive API manufacturers segment is expected to account for the largest share of the APIs market. This can be attributed to the fact that most big pharmaceutical companies possess their API manufacturing facilities and are vertically integrated across the pharmaceutical supply chain. Moreover, innovator companies prefer in-house manufacturing of innovative products to avail economic benefit and prevent technology leakage.

Key Questions addressed by the report:

Where will all these developments take the industry in the mid to long term?

What types of annual and multi-year partnerships are API companies exploring?

Which are the key players in the market and how intense is the competition?

Which are the recent contracts and agreements key players have signed?

What are the recent trends affecting the API manufacturers?

Request Sample Pages@

“North America to dominate the market in 2019.”

In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.

The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).

Recent Developments

In January 2018, Pfizer entered into a collaboration with Sangamo Therapeutics, Inc. (US) for the development of a potential gene therapy to treat amyotrophic lateral sclerosis (ALS).

In May 2018, Novartis acquired AveXis, a clinical-stage gene therapy company, to develop a gene-based treatment for spinal muscular atrophy.

In January 2018, Sanofi acquired Ablynx, a biopharmaceutical company to strengthen its platform for growth in rare blood disorders.

In January 2018, Sanofi and Alnylam Pharmaceuticals, Inc. (US) announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize the development and commercialization of products prescribed for the treatment of rare genetic diseases.

Feel FREE to Talk to Our Research Experts for More Detailed Information@

on March 25 at 12:10

Comments (0)

Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2020 Content By Members. All Rights Reserved.